Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Last Updated
In the Matter of Schering-Plough Corporation, a corporation, and Merck & Co. Inc., a corporation.
FTC Matter/File Number
091 0075
Docket Number
C-4268
Enforcement Type
Part 2 Consents

Case Summary

The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.